NYSEHealth CareMedical - DistributionSnapshot 2026-08-31
Reading MCK? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Broken: Primary pillar broken — Oncology & Multispecialty segment revenue growth: rev +8.0% vs 20.0%.
McKesson grows earnings about 13% to 16% yearly. Its Oncology segment revenue rose 31% last year. The company increased share buybacks to $7.7 billion. Profit margins remain stable with steady cash flow.
Growth could slow if acquisitions in Oncology stall. Divestitures may disrupt revenue. Share repurchases might not continue at current levels.
The price is about 21% below our fair value near $1014. Analysts expect 8% revenue growth, while we see stronger EPS growth ahead.
Breaks if: EPS growth falls below 13% YoY next fiscal year
Breaks if: Oncology segment revenue growth falls below 20% YoY next fiscal year
Authorization falls significantly below $7 billion within next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on long-term growth. The current thesis state is intact, supported by strong recent financial performance and management's commitment to growth targets.
The market seems to price MCK as relatively cheap compared to its peers, with a slight expectations gap indicating that some cautiousness is already reflected. The valuation suggests that while there is fragility in execution quality, it is not fully priced in.
Management has shown strong execution in expanding key segments like Oncology & Multispecialty, with significant revenue growth. However, there is a moderate risk of missing future guidance, especially given the recent cybersecurity incident and historical performance.
The thesis hinges on MCK's ability to maintain its growth trajectory and manage risks effectively. Key factors include the performance of sector peers and overall economic conditions, particularly job growth and recession fears.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The acquisition of Precision Medicine Group will expand the Oncology segment. This move aligns with growth in the Oncology and Multispecialty segment.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, MCK's fundamentals are strong, but caution is warranted due to potential risks. Not investment advice.
